We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01286753
First Posted: January 31, 2011
Last Update Posted: September 7, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hoffmann-La Roche
Results First Submitted: July 22, 2016  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Neoplasms
Intervention: Drug: Vemurafenib

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Written informed consent for participation in the study was obtained before performing any study-specific screening tests or evaluations.

Reporting Groups
  Description
Tyrosine Kinase Inhibitor (TKI) Naive Vemurafenib 960 milligrams (mg) orally twice daily in participants naive to any prior systemic TKI therapy.
TKI Experienced Vemurafenib 960 mg orally twice daily in participants previously treated with TKI therapy active against vascular endothelial growth factor receptor 2 (VEGFR).

Participant Flow:   Overall Study
    Tyrosine Kinase Inhibitor (TKI) Naive   TKI Experienced
STARTED   26   25 
COMPLETED   0   0 
NOT COMPLETED   26   25 
Adverse Event                7                6 
Progression                11                13 
Refused Treatment                1                0 
Withdrawal of Consent                0                2 
Discontinued to Join Extension Study                6                4 
Participant to Receive Radiotherapy                1                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent-to-Treat population, defined as all enrolled participants.

Reporting Groups
  Description
TKI Naive Vemurafenib 960 mg orally twice daily in participants naive to any prior systemic TKI therapy.
TKI Experienced Vemurafenib 960 mg orally twice daily in participants previously treated with TKI therapy active against VEGFR.
Total Total of all reporting groups

Baseline Measures
   TKI Naive   TKI Experienced   Total 
Overall Participants Analyzed 
[Units: Participants]
 26   25   51 
Age 
[Units: Years]
Mean (Standard Deviation)
 62.9  (13.5)   65.2  (9.1)   64.0  (11.5) 
Gender 
[Units: Participants]
     
Female   11   12   23 
Male   15   13   28 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Best Overall Response Rate in TKI-Naive Participants   [ Time Frame: Up to approximately 4 years ]

2.  Secondary:   Best Overall Response Rate in TKI-Experienced Participants   [ Time Frame: Up to approximately 4 years ]

3.  Secondary:   Clinical Benefit Rate   [ Time Frame: Up to approximately 4 years ]

4.  Secondary:   Duration of Response   [ Time Frame: From the date of first qualifying response to the date of PD or death for any cause (up to approximately 4 years) ]

5.  Secondary:   Progression-Free Survival   [ Time Frame: From the day of first treatment until the first documented PD or death (up to approximately 4 years) ]

6.  Secondary:   Overall Survival   [ Time Frame: From the date of first treatment to the date of death for any cause (up to approximately 4 years) ]

7.  Secondary:   Percentage of Participants With Adverse Events   [ Time Frame: Baseline until 28 days after the last dose of study treatment or until initiation of another anti-cancer therapy, whichever occurred first (up to approximately 4 years) ]

8.  Secondary:   Pharmacokinetics of Vemurafenib: Area Under the Concentration-Time Curve (AUC)   [ Time Frame: Up to approximately 4 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Medical Communications
Organization: Hoffmann-La Roche
phone: 800 821-8590
e-mail: genentech@druginfo.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01286753     History of Changes
Other Study ID Numbers: NO25530
2010-024133-23
First Submitted: January 28, 2011
First Posted: January 31, 2011
Results First Submitted: July 22, 2016
Results First Posted: September 7, 2016
Last Update Posted: September 7, 2016